financetom
Business
financetom
/
Business
/
Emirates boss says unhappy with Boeing delays in fixing 777X problems
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Emirates boss says unhappy with Boeing delays in fixing 777X problems
May 9, 2024 8:41 AM

(Corrects 4th paragraph in May 7 article to say twin "aisle" jets, not "engined")

DUBAI (Reuters) -The chairman of Dubai carrier Emirates said on Tuesday he was not happy with Boeing, which he said had promised him that it would fix issues plaguing the U.S. planemaker, including its 777X program.

Emirates is the biggest customer of Boeing's 777X, which will be the industry's largest twin-engined jet with around 400 seats. But its entry into service has been delayed by about five years due to problems including certification delays.

Sheikh Ahmed bin Saeed Al Maktoum, a key member of Dubai's ruling family and member of government, said he believed the certification would now happen in the first quarter of 2025.

But he said the uncertainty over when it would be delivered was putting pressure on Emirates, by far the Middle East's biggest airline and which only uses large twin-aisle jets.

Sheikh Ahmed said the airline would keep using existing jets for longer than expected as a result of the 777X delays.

"I'm not happy," he told reporters at the Arabian Travel Market tourism trade exhibition in Dubai.

"They promised they would do their best to fix it," he said of Boeing's new management when asked about the issues it faces.

Boeing is overhauling its management amid mounting pressure from airlines, regulators and investors as it grapples with a growing crisis following a January mid-air panel blowout on a 737 MAX plane.

(Reporting by Alexander Cornwell; Editing by Emelia Sithole-Matarise)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Payfare Receives Management Cease Trade Order, Reaffirms Q4, Full Year 2023 Guidance
Payfare Receives Management Cease Trade Order, Reaffirms Q4, Full Year 2023 Guidance
Apr 4, 2024
06:18 AM EDT, 04/04/2024 (MT Newswires) -- Fintech company Payfare Inc. ( PYFRF ) , which rose 3.4% yesterday, overnight Wednesday said the Ontario Securities Commission has granted Payfare's ( PYFRF ) request for a management cease trade order (MCTO) in respect of its delay in filing its audited annual financial statements, management's discussion and analysis, annual information form and...
Why BlackBerry Shares Are Rising Premarket Thursday
Why BlackBerry Shares Are Rising Premarket Thursday
Apr 4, 2024
BlackBerry Limited ( BB ) shares are trading higher after it reported fourth-quarter FY24 results. Revenue of $173 million came better than $151 million a year ago, beating the consensus of $154.8 million. IoT revenue reached an all-time quarterly record of $66 million, up 25% Y/Y, and Cybersecurity revenue rose 5% Y/Y to $92 million. Adjusted gross margin expanded to 75% from...
Update: BlackBerry Swings to Fiscal Q4 Earnings as Sales Rise; Sets Fiscal Q1, Full-Year Guidance; Shares Jump Premarket
Update: BlackBerry Swings to Fiscal Q4 Earnings as Sales Rise; Sets Fiscal Q1, Full-Year Guidance; Shares Jump Premarket
Apr 4, 2024
04:57 AM EDT, 04/04/2024 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.) BlackBerry's (BB) shares were up 8.2% in premarket activity Thursday after the technology firm swung back into the black in fiscal Q4, surprising analysts who expected non-GAAP losses to widen. The company reported fiscal Q4 non-GAAP earnings late Wednesday of $0.03...
UK watchdog says Theramex-Viatris deal raises competition concerns
UK watchdog says Theramex-Viatris deal raises competition concerns
Apr 4, 2024
April 4 (Reuters) - Britain's competition watchdog said Theramex's purchase of European rights to two of Viatris' ( VTRS ) women's healthcare products ranges could lead to higher prices and lesser options for hormone replacement therapy treatments. Drugmaker Viatris agreed to sell its rights to Duphaston and Femoston product ranges to London-based Theramex in October. (Reporting by Prerna Bedi in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved